A detailed history of Park Place Capital Corp transactions in Repligen Corp stock. As of the latest transaction made, Park Place Capital Corp holds 186 shares of RGEN stock, worth $23,199. This represents 0.01% of its overall portfolio holdings.

Number of Shares
186
Previous 162 14.81%
Holding current value
$23,199
Previous $20,000 35.0%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$119.79 - $167.35 $2,874 - $4,016
24 Added 14.81%
186 $27,000
Q2 2024

Jul 02, 2024

SELL
$120.0 - $182.95 $9,480 - $14,453
-79 Reduced 32.78%
162 $20,000
Q1 2024

Apr 18, 2024

BUY
$170.78 - $208.42 $1,195 - $1,458
7 Added 2.99%
241 $44,000
Q4 2023

Jan 24, 2024

SELL
$114.17 - $185.35 $2,169 - $3,521
-19 Reduced 7.51%
234 $42,000
Q3 2023

Oct 17, 2023

BUY
$138.78 - $176.51 $16,653 - $21,181
120 Added 90.23%
253 $40,000
Q2 2023

Aug 04, 2023

BUY
$138.42 - $180.31 $18,409 - $23,981
133 New
133 $18,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Park Place Capital Corp Portfolio

Follow Park Place Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Place Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Park Place Capital Corp with notifications on news.